ZYUS Life Sciences Realigns Operations to Advance Non-Opioid Drug Pipeline
SASKATOON, Saskatchewan, June 11, 2026 ZYUS Life Sciences Corporation announced a strategic corporate realignment designed to sharpen its focus...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SASKATOON, Saskatchewan, June 11, 2026 ZYUS Life Sciences Corporation announced a strategic corporate realignment designed to sharpen its focus...
TORONTO, June 9, 2026 SpinaFX Medical has achieved a major regulatory milestone after receiving U.S. Food and Drug Administration...
SOLON, Ohio, June 10, 2026 Multi Radiance Medical announced that the U.S. Food and Drug Administration (FDA) has granted...
GRÄFELFING, Germany – June 9, 2026 VERTANICAL has achieved a major milestone in chronic pain treatment after receiving Germany’s...
SANDWICH, UK, June 3, 2026 Levicept Ltd announced new data from its Phase 2 clinical trial of LEVI-04, a...
BERKELEY HEIGHTS, N.J., May 28, 2026 Tonix Pharmaceuticals presented new real-world data at the 2026 American Society of Clinical...
BURLINGTON, Massachusetts, May 26, 2026 Consano Bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for painful...
SAN DIEGO, April 30, 2026 Contineum Therapeutics, Inc. announced positive topline results from its Phase 1b clinical trial of...
THE WOODLANDS, Texas | January 9, 2026 — Autonomix Medical, Inc. has reported compelling proof-of-concept (PoC) clinical data demonstrating...
SEOUL, South Korea, Oct. 13, 2025 — NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), a South Korea-based innovative medical device company,...
